You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Immunoglobulin A Nephropathy: A Call to Action for Personalized Risk Assessment and Timely Management

  • Authors: Jonathan Barratt, FRCP, PhD​; Rosanna Coppo, MD, FERA​; Hong Zhang, MD, PhD​
  • CPD Released: 4/4/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 4/4/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US PCPs, nephrologists, and allergist & clinical immunologists.

The goal of this activity is that learners will be better able to discuss how updated guidelines and the recently developed immunoglobulin A nephropathy (IgAN) Risk-Prediction Tool can help identify patients at high-risk of progression, the role of proteinuria in guiding treatment decisions and how the field is moving in the direction of “personalized medicine."

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Guideline updates for identification and management of patients at high-risk of progression
    • Role of proteinuria in guiding management of IgAN
    • Effective management of IgAN to reduce proteinuria and prevent end-stage renal disease (ESRD)


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.


Faculty

  • Jonathan Barratt, FRCP, PhD

    Professor of Renal Medicine
    Department of Cardiovascular Sciences
    University of Leicester
    Nephrologist
    John Walls Renal Unit
    University Hospitals of Leicester NHS Trust
    Leicester, United Kingdom

    Disclosures

    Consultant or advisor for: Alnylam Pharmaceuticals; Argenx; Astellas; Biocryst; Calliditas; Chinook Therapeutics; Dimerix; Galapagos; Novartis; Omeros; Travere Therapeutics; UCB; Vera Therapeutics; Visterra
    Research funding from: Argenx; Calliditas; Chinook Therapeutics; Galapagos; GSK; Novartis; Travere Therapeutics

  • Rosanna Coppo, MD, FERA

    Former Director
    Regina Margherita Children’s
    University Hospital
    Torino, Italy

    Disclosures

    Consultant or advisor for: Amgen; Argenx; Calliditas; Menarini; Novartis; Ostuka; Reata; Travere

  • Hong Zhang, MD, PhD

    Professor of Medicine
    Renal Division
    Peking University First Hospital
    Peking University Institute of
    Nephrology
    Beijing, China

    Disclosures

    Consultant or advisor for: Calliditas; Chinook; Novartis; Omeros

Editor

  • Rita Moreira Da Silva, PharmD, MA, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Rita Moreira Da Silva, PharmD, MA, PhD, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Immunoglobulin A Nephropathy: A Call to Action for Personalized Risk Assessment and Timely Management

Authors: Jonathan Barratt, FRCP, PhD​; Rosanna Coppo, MD, FERA​; Hong Zhang, MD, PhD​Faculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 4/4/2022

Valid for credit through: 4/4/2023, 11:59 PM EST

processing....

中文文字稿

Download the pdf.

« Return to: Immunoglobulin A Nephropathy: A Call to Action for Personalized Risk Assessment and Timely Management
  • Print